Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4081 Target Snapshot

Tissue factor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
200Compounds
31Assays
0Approved Drugs
171.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Tissue factor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P13726. Start with cancer, then reuse UniProt P13726 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cancer, then reuse UniProt P13726 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
cancer

Tissue factor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with cancer because it currently carries approved-linked support. Linked drugs include TISOTUMAB VEDOTIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tissue factor as ChEMBL target CHEMBL4081, mapped to UniProt P13726. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tissue factor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4081
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P13726
Tissue factor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Tissue factor is the right protein anchor across sources, using UniProt P13726 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameTissue factor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP13726
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTissue factor
UniProt AccessionP13726
Component TypeProtein
Sequence Length295 aa

Tissue factor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Tissue factor, mapped to UniProt P13726. Sequence length is 295 aa.

Mapped IDP13726
Review nameTissue factor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Tissue factor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugTISOTUMAB VEDOTIN
Approved-linked Approved
cervical cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugTISOTUMAB VEDOTIN
Approved-linked Approved
neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugTISOTUMAB VEDOTIN
Clinical signal Phase II
fallopian tube cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugTISOTUMAB VEDOTIN
Clinical signal Phase II
ovarian cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugTISOTUMAB VEDOTIN
Clinical signal Phase II
peritoneum cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugTISOTUMAB VEDOTIN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with cancer because it currently carries approved-linked support. Linked drugs include TISOTUMAB VEDOTIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Phase III
1
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC50122.0
KI49.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4066780 10.55 IC50 0.028 Preclinical
CHEMBL510111 10.46 IC50 0.035 Preclinical
CHEMBL17201 10.28 IC50 0.053 Preclinical
CHEMBL230128 10.27 IC50 0.054 Preclinical
CHEMBL4070749 10.11 IC50 0.078 Preclinical
CHEMBL2047219 10.02 IC50 0.095 Preclinical
CHEMBL276473 9.92 IC50 0.12 Preclinical
CHEMBL4092579 9.66 IC50 0.221 Preclinical
CHEMBL470029 9.66 IC50 0.221 Preclinical
CHEMBL486400 9.66 IC50 0.221 Preclinical
Distribution

pChEMBL Value Distribution

6
5.0
9
5.5
17
6.0
35
6.5
30
7.0
29
7.5
9
8.0
5
8.5
4
9.0
6
9.5
pChEMBL
Assay Landscape

Assay Landscape

31
Total Assays
156
Tested Compounds
2
Assay Types
Binding — 26 assays, 156 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 16 54 8.0
single protein format 8 60 6.7
protein complex format 2 42 6.9
Functional — 5 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-free format 3 0 —
assay format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine